Concepedia

Author

Jian Zhang

Fudan University Shanghai Cancer CenterORCID

Also Known As

J. Zhang, Jian Zhang

36

Publications

566

Citations

10

H-Index

16

Concepts

All Affiliations

Fudan University Shanghai Cancer CenterShanghai Medical College of Fudan University
JZ

About

Jian Zhang is an author at Fudan University Shanghai Cancer Center specializing in tumor biology, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

89

2

Pathology

2

2

89

3

Immunology

1

1

15

4

Cell Development

1

1

15

5

Hypertension

1

1

74

Jian Zhang

×

8

Publications

290

Citations

8

H-Index

YearCitations

Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy

Minhao Fan, Jian Zhang, Zhonghua Wang,

Breast Cancer Research and Treatment

2013

74

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer

Yannan Zhao, Chengcheng Gong, Zhonghua Wang,

Oncotarget

2017

63

Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours

Jian Zhang, Rujiao Liu, Shuiping Gao,

npj Breast Cancer

2023

46

Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway

Zhenhua Wu, Lin Chen, Mingming Liu,

PLoS ONE

2016

39

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial

Doudou Li, Zhonghua Tao, Biyun Wang,

npj Breast Cancer

2022

27

PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR

Jia Jin, Leiping Wang, Zhonghua Tao,

Molecular Medicine Reports

2020

15

GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer

Jian Zhang, Ying Wu, Xichun Hu,

Oncotarget

2017

14

9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.

Jian Zhang, Rujiao Liu, Shuiping Gao,

Journal of Clinical Oncology

2024

12

Page 1